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Atrial Fibrillation
Following Transcatheter
Aortic Valve Implantation
Do We Underestimate
its Frequency and Impact?*
Bernard Iung, MD, Dominique Himbert, MD,
Alec Vahanian, MD
Paris, France
The paper by Amat-Santos et al. (1) in this issue of the
Journal deserves attention because of its originality and its
potential implications concerning the post-procedural man-
agement of patients undergoing transcatheter aortic valve
implantation (TAVI).
See page 178
The issue of atrial fibrillation (AF) following TAVI may
seem of limited interest at first sight, and this is probably the
reason why this issue has not been addressed in depth so far.
First, AF is usually a more important concern in mitral than
in aortic valve diseases. Second, the occurrence of AF
following surgery under cardiopulmonary bypass is generally
interpreted as a consequence of perioperative systemic and
local inflammatory reaction and/or changes in beta-
adrenergic tone, these factors not being encountered with
TAVI (2). Third, post-operative AF is generally considered
to be more a common event early after surgery rather than
a potential cause of complications. As an illustration, AF is
not included in the guidelines for reporting mortality and
morbidity after cardiac valve interventions (3). On the other
hand, the Valve Academic Research Consortium has drawn
attention to AF following TAVI (4).
In this context, the first unexpected finding is a frequency
as high as 32% of new-onset AF within the 30 days
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Lifesciences and Siemens.following TAVI. A strength of the study by Amat-Santos et
al. (1) is the use of continuous monitoring of the electro-
cardiogram during the entire hospital stay. This enables the
frequency and time-distribution of AF to be reliably as-
sessed. Although the majority of cases of AF occur early
after intervention, the time course of AF differs between
TAVI and cardiac surgery. In the present study, 36% of
cases of AF occurred during the procedure and 27% be-
tween the procedure and day 2. After cardiac surgery, AF
incidence is below 10% during the first 24 h, peaks at
post-operative day 2, and subsequently decreases (2). These
differences may be partly explained by differences in sys-
temic inflammation because the time distribution of post-
operative AF is very close to the evolution of C-reactive
protein blood concentrations (2). In the paper by Amat-
Santos (1), a third of AF episodes lasted less than 1 h, which
emphasizes that they are likely to be ignored if not diag-
nosed using systematic ECG monitoring. However, the
findings of Amat-Santos et al. (1) cannot be extrapolated to
all cases of TAVI. The Edwards SAPIEN prosthesis
(Edwards Lifesciences, Irvine, California) was exclusively
used in this series, and the same study should be conducted
with the Medtronic CoreValve prosthesis (Medtronic, Min-
neapolis, Minnesota). The transapical approach was used in
72% of cases, and the incidence of post-procedural AF was
only 16% for transfemoral TAVI, which is considered as the
first-line approach by most teams.
The 2 factors associated with the occurrence of new-onset
AF after TAVI were left atrial enlargement and the use of
the transapical approach. Although expected, the relation-
ship between left atrial enlargement and post-operative AF
has been found only in certain series (2). This may be partly
related to the inaccuracy of M-mode echocardiographic
measurements of left atrial diameter to assess left atrial size.
Multidimensional measurements should be preferred since
they enable left atrial volume to be assessed with a better
accuracy and reproducibility (5). The relationship between the
transapical approach and the occurrence of AF after TAVI
illustrates the role of cardiac tissue attrition as one of the
mechanisms promoting AF after cardiac intervention. The
local inflammatory reaction due to pericardial opening and
subsequent healing contributes to an increased frequency of
post-operative AF, and the same mechanisms can be ex-
pected after TAVI using a transapical approach (2). Non-
cardiac thoracic surgery is also a condition increasing the
risk of post-operative AF, which may account for the higher
incidence of AF due to thoracotomy inherent in the
transapical approach (6). The combination of predictive
factors of AF after TAVI may be useful to identify patients
who are at high risk of developing post-procedural AF.
Besides frequency and predictive factors, one of the most
clinically relevant issues addressed in the paper by Amat-
Santos et al. (1) is the assessment of the impact of AF after
TAVI. These findings should be interpreted with caution,
given the small number of embolic events (9 at 30 days) and
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therapy. However, the significant relationship between
post-procedural AF and embolic events is a relevant contri-
bution in the analysis of the potential causes of embolic
events after TAVI. Concerns regarding the risk of stroke
were raised following the recent PARTNER (Placement of
Aortic Transcatheter Valve) High-Risk randomized trial,
which showed an increased frequency of stroke at 30 days
and 1 year after TAVI as compared with surgical aortic valve
replacement (7). Despite the number of mechanisms that
may be involved in stroke after TAVI, the particularly
strong relationship between post-procedural AF and stroke
occurring after 24 h (1) suggests that a cardioembolic origin
significantly contributes to stroke after TAVI.
Even if the relationship between post-procedural AF and
stroke needs to be confirmed by studies comprising a higher
number of events, the association raises questions regarding
the most appropriate antithrombotic therapy following
TAVI. The association of aspirin and clopidogrel is the
current standard treatment for 3 to 6 months following
TAVI, but this relies on empirical rather than evidence-
based grounds. The high number of episodes of AF lasting
1 h in the paper by Amat-Santos et al. (1) raises serious
concerns about the possibility of recommending an individ-
ualized strategy consisting of combining anticoagulant ther-
apy with a single antiplatelet drug as soon as patients
experience AF after TAVI. On the other hand, a systematic
combination of vitamin K blockers and an antiplatelet drug
would expose patients to a higher bleeding risk without a
compensatory benefit in the prevention of stroke for the
two-thirds of patients who do not develop AF after TAVI.
A recent paper suggests that aspirin alone may be as effective
as aspirin and clopidogrel after TAVI (8). Larger trials are
obviously needed to optimize antithrombotic therapy after
TAVI. We should avoid reproducing with TAVI the same
mistakes that were made with surgical aortic valve replace-
ment using a bioprosthesis. Vitamin K blockers were ini-
tially recommended during the first 3 post-operative months
(9,10). However, this was based mainly on retrospective
observational series with many sources of bias (11). The
usefulness of vitamin K blockers in this setting has been
challenged, and the alternative use of aspirin is now explic-
itly recommended by certain authors (12,13).
The paper by Amat-Santos et al. (1) has the merit of
drawing attention to the frequency and the potential impact
of AF occurring after TAVI. The potential contribution of
post-procedural AF to the occurrence of stroke after TAVI
highlights the need to improve the identification of patients
at risk, to test pharmacological approaches to reduce theincidence of AF, and to conduct randomized trials to refine
antithrombotic therapy in this setting.
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